We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Alzheimer’s Research Group Calls on FDA to Ease Clinical Trial Pathway
Alzheimer’s Research Group Calls on FDA to Ease Clinical Trial Pathway
The FDA could significantly improve clinical trial design and boost investment in Alzheimer’s research and treatment, if it required applicants to meet one endpoint in clinical trials of drugs for Alzheimer’s disease, according to an Alzheimer’s research advocacy group.